Access Update- #30

I’d like to welcome all of our new Access subscribers. I’m confident that you’ll not only be pleased with your subscription, but also agree that Access is unlike any other newsletter or research service available to individual investors.

Our performance so far has been stellar. As of yesterday’s close the portfolio is up 24% in just five months. That includes gains of 38% in Electro-Optical Sciences (Nasdaq: MELA) and 34% in ViroPharma (Nasdaq: VPHM).

We believe this is just the beginning, as our newest recommendation, Synta Pharmaceuticals (Nasdaq: SNTA) has an incredible opportunity to potentially launch the first drug ever approved for late stage melanoma.

I hope by now all of you have had the chance to read the report , which we told you about on Monday. If for some reason you missed it, click here .

As for the rest of our portfolio, it’s been a slow news week. However, biotech and healthcare stocks tend to pick up in the fall, as investor conferences begin right after Labor Day. SNTA and VPHM will kick things off with presentations on Thursday, September 4th at the BioCentury Newsmakers in the Biotech Industry Conference. Earlier that morning, VPHM will also present at the Thomas Weisel Partners 2008 Healthcare Conference.

Typically, major news stories do not break at these conferences, but the companies do stir up institutional interest in their stocks, provided they have a good story to tell. And we believe that our portfolio companies have great stories.

With some near-term catalysts coming up and the busy conference schedule over the next few months, we expect the stocks to continue to rise.

Have a great holiday weekend.

Marc Lichtenfeld
Director of Research
Access Research Group

Stock
Symbol
Current Price
Comments

Synta Pharmaceuticals

SNTA

$8.84

Buy up to $13.00

ViroPharma

VPHM

$14.72

Buy up to $12.50

Cytori Therapeutics

CYTX

$6.30

Buy up to $8

Electro-Optical Sciences

MELA

$7.01

Buy up to $5.75